2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Emerging Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Pathogenesis, Immune Mechanism, Microbiome, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, Autoimmune Disorders, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

5924 Allogeneic CD19/BCMA CAR-T therapy in refractory CTD-ITP: Phase 1 safety and immune repertoire reconstitution

Mengtao Li, Yingyong Xu, MD, PhD, MBA2, Runxia Gu, MD3, Xu Feng4, Jiapan Hu5, mucong Li6, lihua wu7, shuning wei8, liyin peng9, can huang10, ziqian wang11, li wang12, zhenzhen wang13, shangzhu zhang14, wei bai15, shikai hu16, junyan qian17, chaojun hu18, xiyan wang19, tony ho20, Jianxiang Wang Sr, MD, PhD21, Luhan Yang, PhD22, Yanan Yue23, Jiuliang Zhao24, Ying Wang, MD, PhD25
1 Peking Union Medical College Hospital, beijing, China
2 Qihan Biotechnology, Hangzhou, China
3 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Peking Union Medical College Hospital, beijing, China
7 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
8 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
9 Peking Union Medical College Hospital, beijing, China
10 Peking Union Medical College Hospital, beijing, China
11 Peking Union Medical College Hospital, beijing, China
12 Peking Union Medical College Hospital, beijing, China
13 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
14 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
15 Peking Union Medical College Hospital, beijing, China
16 Peking Union Medical College Hospital, beijing, China
17 Peking Union Medical College Hospital, beijing, China
18 Peking Union Medical College Hospital, beijing, China
19 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
20 Qihan Biotechnology, Hangzhou, China
21 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China
22 Qihan Biotechnology, Hangzhou, China
23 Qihan Biotechnology, Hangzhou, China
24 Peking Union Medical College Hospital, beijing, China
25 Institute of Hematology & Blood Diseases Hospital, CAMS/PUMC, tianjing, China

Background: Connective tissue disease–associated immune thrombocytopenia (CTD-ITP), most commonly secondary to systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS), or Sjögren's disease, is a severe, autoantibody-driven cytopenia for which treatment options remain limited.. Approximately 20% of patients are refractory to corticosteroids, immunosuppressants, and B-cell-targeted therapies. While autologous CD19 CAR-T has achieved remission in SLE-ITP, manufacturing delays and incomplete plasma cell elimination remain limitations. QT-019B, an allogeneic dual-target CD19/BCMA CAR-T designed for immediate availability and immune reset, has received FDA Fast Track, RMAT, and BTD for SLE-ITP.

Methods: In this Phase 1 investigator-initiated trial, 11 patients with refractory CTD-ITP (7 SLE, 3 primary APS, 1 overlapping SLE/APS) received a single infusion of QT-019B at 1×106 or 3×106 cells/kg following lymphodepletion with fludarabine and cyclophosphamide. Endpoints included safety, dose-limiting toxicity, CAR-T pharmacokinetics, B-cell depletion, and platelet response.

Results: At a median follow-up of 9 months (range 6–15), 10 of 11 patients achieved CR (platelet count ≥100×10?/L) within a median of 11 days. One patient with baseline bone marrow hypoplasia did not meet the CR criterion  but showed megakaryocyte recovery by month 4 and near-normal platelets by month 15. Of 10 CR patients, 9 maintained durable CR and 1 relapsed on day 141. All responders discontinued immunosuppressants. Serologic markers normalized in all evaluable patients. CAR-T cells expanded robustly with median peak at 11.5 days. No DLTs, grade ≥2 CRS, ICANS, or GVHD occurred. Four patients had grade 1 CRS. Hypogammaglobulinemia occurred in 9 patients without serious infections. scRNA-seq showed immune repertoire resetting characterized by a predominance of immature and naïve B-cell and reduced somatic hypermutation.

Conclusions: Allogeneic dual-target CD19/BCMA CAR-T QT-019B achieved rapid, durable remission in refractory CTD-ITP with an excellent safety profile. These findings support progression of this off-the-shelf platform for autoantibody-driven autoimmune cytopenias.

Ying Wang, MD, PhD: No relevant conflicts of interest to declare.